Improved Quality of Life in Children With Cystic Fibrosis Who Received Transmembrane Conductance Regulator Modulators
Acta Paediatrica · 2026-06 · 115 (6) · 1283-1289
DOI: 10.1111/apa.70498 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Acta Paediatrica, online erschienen am 11.03.2026. Verfasst von Marcus Svedberg und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Paediatrics, Institute of Clinical Sciences, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden. Hauptthemen laut MEDLINE: Cystic Fibrosis, Quality of Life, Quinolones, Aminophenols. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Drottning Silvias barnsjukhus.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Aim
Children with cystic fibrosis (CF) face substantial daily treatment burdens and the effects of transmembrane conductance regulator modulators on these have not been sufficiently described. We evaluated changes in treatment burden after elexacaftor tezacaftor ivacaftor (ETI) was initiated.
Methods
This prospective observational study comprised children aged six to 17 years from three Swedish paediatric CF centres. They were enrolled from 7 December 2022 to 30 June 2023, before ETI was initiated. Their health‐related quality of life, treatment burden, and adherence were assessed at baseline and at six and 12 months.
Results
We studied 62 children who initiated ETI and were followed up to 12 months. The mean standard deviation (SD) treatment burden score improved by 4.9 points (95% confidence interval (CI) −0.7 to 10.6, p = 0.087), from 67.6 (±20.6) at baseline to 72.5 (±17.6) at 12 months. The mean daily time spent on inhalation therapy and airway clearance decreased from 91.9 (±37.3) to 70.4 (±23.6) minutes ( p < 0.001). Mean inhalation time per session fell by 7 min (95% CI −10.5 to −3.3, p < 0.001) and airway clearance time by 4 min (95% CI −6.7 to −1.5, p = 0.003).
Conclusion
Treatment burden, particularly daily inhalation and airway clearance time, decreased after ETI initiation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Paediatrics, Institute of Clinical Sciences, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden.
- Department of Paediatrics, Queen Silvia's Children's Hospital, Gothenburg, Sweden.
- Centre for Digital Health, Sahlgrenska University Hospital, Gothenburg, Sweden.
- Department of Paediatrics, Skåne University Hospital, Lund, Sweden.
- Department of Paediatrics, Uppsala University Hospital, Uppsala, Sweden.
- Statistiska Konsultgruppen Sweden, Gothenburg, Sweden.
ORCID-Profile: Marcus Svedberg, Henrik Imberg
Förderung
- Drottning Silvias barnsjukhus
Zitieren
APA
Svedberg, M., Lundqvist, F., Östrand, H. A., Krantz, C., Ekman, P., & Imberg, H. (2026). Improved Quality of Life in Children With Cystic Fibrosis Who Received Transmembrane Conductance Regulator Modulators. Acta Paediatrica, 115(6), 1283-1289. https://doi.org/10.1111/apa.70498
Vancouver
Svedberg M, Lundqvist F, Östrand HA, Krantz C, Ekman P, Imberg H. Improved Quality of Life in Children With Cystic Fibrosis Who Received Transmembrane Conductance Regulator Modulators. Acta Paediatrica. 2026;115(6):1283-1289. doi:10.1111/apa.70498
BibTeX
@article{Svedberg2026,
author = {Svedberg, Marcus and Lundqvist, Frida and Östrand, Huda Abdulahi and Krantz, Christina and Ekman, Per and Imberg, Henrik},
title = {Improved Quality of Life in Children With Cystic Fibrosis Who Received Transmembrane Conductance Regulator Modulators},
journal = {Acta Paediatrica},
year = {2026},
volume = {115},
number = {6},
pages = {1283--1289},
doi = {10.1111/apa.70498}
}
EUVIMED